14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $14.00 $25.47 Thursday, 2nd May 2024 DCPH stock ended at $25.38. This is 0.0789% more than the trading day before Wednesday, 1st May 2024. During the day the stock fluctuated 0.493% from a day low at $25.35 to a day high of $25.47.
90 days $13.86 $25.47
52 weeks $9.90 $25.47

Historical Deciphera Pharmaceuticals Inc prices

Date Open High Low Close Volume
Feb 21, 2024 $15.38 $15.57 $15.12 $15.40 495 383
Feb 20, 2024 $15.51 $15.92 $15.36 $15.55 347 610
Feb 16, 2024 $15.76 $15.85 $15.38 $15.67 575 114
Feb 15, 2024 $15.40 $15.97 $15.40 $15.92 433 952
Feb 14, 2024 $14.75 $15.36 $14.75 $15.28 522 575
Feb 13, 2024 $14.99 $15.28 $14.23 $14.50 562 346
Feb 12, 2024 $15.67 $16.14 $15.38 $15.58 679 053
Feb 09, 2024 $14.21 $15.75 $14.16 $15.73 694 900
Feb 08, 2024 $14.04 $14.28 $13.86 $14.17 453 119
Feb 07, 2024 $14.91 $14.91 $13.98 $14.02 494 543
Feb 06, 2024 $14.92 $15.04 $13.96 $14.83 827 541
Feb 05, 2024 $14.30 $15.02 $14.16 $14.76 393 374
Feb 02, 2024 $14.52 $14.85 $14.28 $14.48 561 394
Feb 01, 2024 $14.33 $14.81 $14.21 $14.76 285 143
Jan 31, 2024 $14.33 $14.85 $14.29 $14.32 321 350
Jan 30, 2024 $14.68 $14.86 $14.22 $14.33 278 707
Jan 29, 2024 $14.27 $15.07 $13.98 $14.95 419 860
Jan 26, 2024 $14.48 $14.80 $14.06 $14.26 301 085
Jan 25, 2024 $14.06 $14.40 $14.06 $14.35 382 354
Jan 24, 2024 $14.49 $14.53 $14.08 $14.13 337 353
Jan 23, 2024 $14.05 $14.47 $13.90 $14.39 1 326 675
Jan 22, 2024 $13.66 $13.96 $13.50 $13.86 436 627
Jan 19, 2024 $13.89 $13.89 $13.38 $13.58 391 301
Jan 18, 2024 $14.14 $14.39 $13.25 $13.89 1 104 157
Jan 17, 2024 $14.25 $14.48 $14.03 $14.14 811 204
Click to get the best stock tips daily for free!

About Deciphera Pharmaceuticals Inc

Deciphera Pharmaceuticals Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. Th... DCPH Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT